MWNA
MACK

Marshall Wace North America’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Marshall Wace North America’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-26,471
Closed -$168K – 1926
2018
Q1 		$168K Buy
+26,471
New +$219K ﹤0.01% 1349

Other funds holding MACK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace North America's MACK Position: Q2 2018 in Review

Marshall Wace North America sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2018, closing a stake of 26,471 shares — an estimated $168K sold.

Marshall Wace North America first reported a position in MACK in Q1 2018 and held it in 1 quarter. The position peaked at $168K in Q1 2018. 76 funds tracked by Wall St. Rank hold MACK as of Q2 2018.

  • Marshall Wace North America reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Marshall Wace North America sold 26,471 Merrimack Pharmaceuticals, Inc. shares in Q2 2018, an estimated $168K.
  • Marshall Wace North America first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Marshall Wace North America's Merrimack Pharmaceuticals, Inc. position peaked at $168K in Q1 2018.
  • 76 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2018.

Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.